Search

Displaying results 2321 - 2330 of 10000 in total
  1. Drug

    Ginsenoside Rg3

    go.drugbank.com/drugs/DB19257
    Investigational

    Ginsenoside Rg3 is under investigation in clinical trial NCT01757366 (Safety and Efficacy of Ginsenoside Rg3 in Combination With First-line Chemotherapy in Advanced Gastric Cancer).

    Synonyms: -d-glucopyranoside, (3.beta.,12.beta.)-12,20-dihydroxydammar-24-en-3-yl 2-o-.beta.-d-glucopyranosyl-, -d-glucopyranosyl-(1->2)-.beta.-d-glucopyranosyldammar-24-ene-3.beta.,12.beta.,20s-triol
  2. Drug

    Danaparoid

    go.drugbank.com/drugs/DB06754
    ApprovedWithdrawn

    Danaparoid possesses a potent antithrombic activity that works by inhibiting activated factor X (Factor Xa) and activated factor II (Factor IIa). … While it was initially approved by the FDA as Orgaran™, danaparoid was withdrawn by Organon International on August 14, 2002, due to a shortage in drug substance by the manufacturer.

  3. Drug

    Camrelizumab

    go.drugbank.com/drugs/DB14776
    Investigational

    Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).

  4. Drug

    Aducanumab

    go.drugbank.com/drugs/DB12274
    ApprovedInvestigational

    [A235720] Development of aducanumab was discontinued in March 2019 when two phase 3 clinical trials did not pass futility analysis; however, Biogen sought FDA approval in October 2019 after reanalyzing … [L34420] Biogen enrolled patients in phase 3 clinical trials in 2015 but increased the size of the trials from 1350 patients to 1650 patients to maintain statistical power in the face of a high standard

  5. Drug

    Depulfavirine

    go.drugbank.com/drugs/DB18890
    Investigational

    Depulfavirine is under investigation in clinical trial NCT05204394 (Study to Evaluate Efficacy and Safety of Switching to VM-1500A-LAI + 2nrtis From the 1st Line Standard of Care Therapy).

    Synonyms: 2-[4-Bromo-3-(3-chloro-5-cyanophenoxy)-2-fluorophenyl]-N-(2-chloro-4-sulfamoylphenyl)acetamide, Benzeneacetamide, N-[4-(aminosulfonyl)-2-chlorophenyl]-4-bromo-3-(3-chloro-5-cyanophenoxy)-2-fluoro-
  6. Drug

    Sebetralstat

    go.drugbank.com/drugs/DB18305
    ApprovedInvestigational

    Hereditary angioedema (HAE) is a rare genetic disease that causes sudden, painful swelling episodes in various body locations that can be life-threatening, particularly when affecting the throat [L53533 … Sebetralstat is the first and only oral on-demand treatment for HAE, providing a convenient alternative to injectable therapies that have been challenging for patients to use [L53538, A274293].

    Synonyms: 1H-Pyrazole-4-carboxamide, N-[(3-fluoro-4-methoxy-2-pyridinyl)methyl]-3-methoxymethyl)-1-[[4-[(2-oxo-1(2H)-pyridinyl)methyl]phenyl]methyl]-, N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyridin-1(2H)-yl)methyl]phenyl}methyl)-1H-pyrazol-4-carboxamideCategories: Drugs Used in Hereditary Angioedema
  7. Drug

    Zalifrelimab

    go.drugbank.com/drugs/DB15632
    Investigational

    Zalifrelimab is under investigation in clinical trial NCT03894215 (Phase 2 Study of Anti-pd-1 Independently or in Combination With Anti-ctla-4 in Second-line Cervical Cancer).

    Synonyms: A human monoclonal antibody targeting cytotoxic T lymphocyte associated protein 4 (ctla4)
  8. Drug

    Saprisartan

    go.drugbank.com/drugs/DB01347
    Experimental

    Saprisartan is an AT1 receptor antagonist. It is based on medications of losartan's prototypical chemical structure. … It is very likely that slow dissociation kinetics from the AT1 receptor underlie insurmountable antagonism [A14009].

    Categories: Angiotensin II receptor antagonists, Angiotensin II Type 1 Receptor Blockers
  9. Drug

    Etranacogene dezaparvovec

    go.drugbank.com/drugs/DB16791
    ApprovedInvestigational

    [L44156] It delivers a copy of the deficient gene that results in cell transduction and an eventual increase in circulating factor IX activity. … [L44181] Hemophilia B is the second most common type of hemophilia,[L44181] with a prevalence of approximately one in 40,000.

  10. Drug

    Fosinopril

    go.drugbank.com/drugs/DB00492
    ApprovedInvestigational

    It is rapidly hydrolyzed to fosinoprilat, its principle active metabolite. Fosinoprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). … Fosinopril may be used to treat mild to moderate hypertension, as an adjunct in the treatment of congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals

    Categories: Agents Acting on the Renin-Angiotensin SystemProducts: FOSINOPRIL Na, Lin-fosinopril